Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Cumberland Pharmaceuticals Adds Vibativ®


 
A.J. Kazimi

Cumberland Pharmaceuticals recently announced the addition of Vibativ® (telavancin) to its growing product lineup. The Nashville-headquartered specialty pharmaceutical company entered into a definitive agreement to acquire Vibativ from Theravance Biopharma in the fourth quarter of 2018.

The FDA-approved injectable antibiotic is used for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin & skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

"Vibativ is a lifesaving product for certain difficult to treat infections, and we are honored to be selected to acquire and transition the brand to our existing hospital acute care infrastructure," said Cumberland Pharmaceuticals CEO A.J. Kazimi, "Our immediate plan for Vibativ is to ensure a smooth transition of the product supply and medical support to current users of the brand. We will then launch our hospital promotion and medical initiatives to help ensure that the product is available to the patients who need it. We are very optimistic about the opportunity that Vibativ will offer Cumberland."

The financial terms include a $20 million payment to Theravance Biopharma upon closing, a $5 million additional payment in early 2019, and tiered royalties of up to 20 percent on future U.S. net product sales. Under the terms of the agreement, Cumberland will assume full responsibility for the product including its marketing, distribution, manufacturing and regulatory activities. Kazimi said Cumberland expects to selectively expand its sales force, medical science liaison and corporate teams to ensure the needed support of Vibativ, as well as its oncology and acute care brands.

 
Share:

Related Articles:


Recent Articles

Integrating AI in Healthcare

Technology has advanced to a point where AI in healthcare is increasingly common. Now the challenge is utilizing data in a way that is not only predictive but also prescriptive to improve health and outcomes.

Read More

AMA Advances New Principles to Put AI into Practice

AHIP isn't the only national organization focused on how AI might be effectively deployed to improve patient engagement, care and interaction with the broader healthcare system.

Read More

State of Technology

Nashville HIT leaders address challenges, accomplishments of the region's thriving healthcare IT market.

Read More

Helping Children and Athletes Breathe Easier

Experiencing shortness of breath during exercise can be extremely distressing, particularly when it occurs in a child, teen or young adult.

Read More

PHYSICIAN SPOTLIGHT: Between Medicine and Technology

When it comes to rolling out new systems, Neal Patel, MD, said listening to users and understanding concerns are critical to success.

Read More

Navigating the Risks of New Healthcare Technologies

New technologies in healthcare hold great promise, but with that promise come risks that must be considered and addressed.

Read More

Tech Talk

Recent news of note in Middle Tennessee's health tech sector.

Read More

Enhancing Access to Care through Technology

Innovative technology allows patients, health plans to schedule appointments online.

Read More

Reimaging Residency

A joint project between Vanderbilt and Ole Miss was one of eight selected by the American Medical Association to reimagine residency programming.

Read More

Tips & Traps: Expert Insights from NMGMA Leadership

NMGMA's president and president-elect share insights borne of experience to help practice managers enhance success.

Read More

Email Print
 
 

 

 


Tags:
Cumberland Pharmaceuticals, Drug-Resistant Infection, Gram-Positive Bacterial Infection, HABP/VABP, Hospital-Aquired and Ventilator-Associated Bacterial Pneumonia, Injectable Antibiotic, MRSA, Telavancin, Vibativ
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: